NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for CNS disorders. The company develops proprietary reformulations and/or new routes of administrations of existing drugs, which are intended to make a clinically meaningful improvement in patients’ lives.
NeuroDerm was acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash. MTPC is a publicly traded company on the Tokyo Stock Exchange.


Product candidates in our portfolio are designed to overcome major deficiencies in current treatments and achieve enhanced clinical efficacy through continuous, controlled administration, primarily subcutaneously or transdermally. NeuroDerm’s product candidates are based on patented reformulations of leading, approved drugs, therefore it is believed that most qualify for an accelerated, lower risk regulatory pathway to marketing approval.

NeuroDerm has developed a portfolio of product candidates that addresses major unmet needs in the field of Parkinson’s disease and cognition. Specifically, in the alleviation of the effects of Parkinson’s disease, the company has several product candidates in different stages of development. These offer a solution for almost every PD patient – from the moderate to the very severe stages of the disease.

These developments are backed by a robust intellectual property portfolio that includes several patent families covering the company’s novel formulations.
NeuroDerm has been supported by grants from the Michael J. Fox Foundation for Parkinson’s Research.
To further explore NeuroDerm’s solutions for PD, please see the Product Portfolio.